15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Audentes reports updated Phase I/II myopathy data for AT132

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported updated interim data from the first cohort of the open-label, dose-escalation, U.S. Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM). The presentation at the American...
20:57 , May 18, 2018 |  BC Extra  |  Clinical News

Audentes rises on additional myopathy data

Audentes Therapeutics Inc. (NASDAQ:BOLD) ended the week at $38.24, up $4.04 (12%), after an oral presentation of updated interim data from the first cohort of the dose-escalation Phase I/II ASPIRO trial testing AT132 in patients...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
21:50 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Audentes reports interim Phase I/II data for XLMTM candidate

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) reported interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy, a rare monogenic disease characterized by extreme muscle...
22:28 , Jan 4, 2018 |  BC Extra  |  Clinical News

Audentes gains on XLMTM readout

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $5.28 (15%) to $40.81 on Thursday after reporting interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy,...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
22:33 , Jun 21, 2017 |  BC Extra  |  Company News

Sarepta gets option for Genethon's DMD gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it gained an option to obtain exclusive U.S. rights from non-profit organization Genethon (Evry, France) to a gene therapy to treat Duchenne muscular dystrophy. The collaboration covers a Genethon preclinical program...
22:01 , Apr 19, 2017 |  BC Extra  |  Financial News

Agios, Audentes price follow-ons

Cancer company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and gene therapy and rare diseases play Audentes Therapeutics Inc. (NASDAQ:BOLD) raised a total of more than $325 million in follow-ons. Agios raised $250 million through the sale of 5.1...
07:00 , Jul 20, 2016 |  BC Extra  |  Top Story

Audentes inches up after pricing $75M IPO

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading Wednesday after raising $75 million through the sale of 5 million shares at $15 in an IPO. The...